Jacob Alexander, James D. Lord, Matthew M. Yeh, Carlos Cuevas, Ramasamy Bakthavatsalam, Kris V. Kowdley – 30 January 2008 – Orthotopic liver transplantation (OLT) is the only effective treatment for end‐stage liver disease due to primary sclerosing cholangitis (PSC). Recurrence of PSC has recently emerged as a leading cause of allograft failure in the long term. There is limited data on risk factors for recurrence of PSC. We performed a retrospective analysis of 69 consecutive patients who underwent a first OLT for PSC over a 14‐year period.

Toru Ikegami, Satoru Imura, Yusuke Arakawa, Mitsuo Shimada – 30 January 2008

Santiago Tome, Adnan Said, Michael R. Lucey – 30 January 2008

Ashokkumar Jain, Rajeev Sharma, Charlotte Ryan, Georgious Tsoulfas, Mark Orloff, Peter Abt, Randeep Kashyap, Pam Batzold, Lisa Sauberman, Saman Safadjou, Maureen Graham, Adel Bozorgzadeh – 30 January 2008 – With the current immunosuppressive regimens, graft loss secondary to immunological reasons after successful liver transplantation is a rarity; acute rejections, however, do occur, with the majority of them being steroid‐responsive.

Evangelos Cholongitas, Vibhakorn Shusang, George V. Papatheodoridis, Laura Marelli, Pinelopi Manousou, Nancy Rolando, David Patch, Keith Rolles, Brian Davidson, Andrew K. Burroughs – 30 January 2008 – Liver transplantation (LT) is the only therapeutic option for end‐stage primary sclerosing cholangitis (PSC), but PSC can recur (rPSC) in some patients after LT. The aim of our study was to evaluate the risk factors associated with rPSC. Between 1989 and 2004, 69 patients receiving transplantation for PSC (42 male, mean age 41.9 yr).

Mazen Alsatie, Prashant Pandya, Naga P. Chalasani – 30 January 2008

Katie Snape, Louise Izatt, Paul Ross, David Ellis, Kathy Mann, John O'Grady – 30 January 2008

Matteo Donadon, Alessandro Giacomoni, Andrea Lauterio, Abdallah Slim, Vincenzo Pirotta, Iacopo Mangoni, Luciano De Carlis – 30 January 2008

Surendra Shenoy, Karen L. Hardinger, Jeffrey Crippin, Kevin Korenblat, Mauricio Lisker‐Melman, Jeffrey A. Lowell, William Chapman – 30 January 2008 – Two‐hour postdose cyclosporine (C2) monitoring is becoming an accepted method of therapeutic drug monitoring, although it is not known whether C2 monitoring is superior to tacrolimus (FK)‐based immunosuppression. The purpose of this trial was to compare the safety, efficacy, and pharmacoeconomics of cyclosporine A (CsA) monitored by C2 levels versus FK monitored by trough levels in de novo liver transplant recipients.

Beyhan Demirhan, Banu Bilezikçi, A. Nihan Haberal, Şinasi Sevmiş, Zübeyde Arat, Mehmet Haberal – 30 January 2008 – During the first episode of acute cellular rejection (ACR) after liver transplantation, centrilobular changes in liver biopsy specimens may be possible indicators of subsequent episodes of ACR, early chronic rejection, or acute graft loss.